Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UCB and Nodality Enter into a Multi-Year Strategic Collaboration

Published: Friday, February 10, 2012
Last Updated: Friday, February 10, 2012
Bookmark and Share
Partnership utilizes Nodality’s SCNP technology to assist the development of several UCB compounds.

UCB Pharma S.A. and Nodality, Inc. have announced a strategic collaboration utilizing Nodality’s proprietary Single Cell Network Profiling (SCNP) technology to assist the development of several UCB compounds.

The agreement establishes a multi-year collaborative investigation focusing initially on immunology disorders.

Based on information generated using Nodality’s technology, the agreement also gives UCB the option to engage Nodality to develop companion diagnostics for UCB’s compounds.

The terms of the agreement, whose details are not disclosed, include an upfront payment, R&D funding, and success-based milestones if all applicable development, regulatory and commercialization milestones are achieved.

In addition, Nodality may be eligible for royalties on future diagnostic sales.

David Parkinson, MD, Chief Executive Officer of Nodality, said, “We are delighted to be working together with UCB’s world class immunology research group to enhance their drug development activities. Based on Nodality’s extensive application of the SCNP platform to malignant and autoimmune diseases, we believe that we will be able to add significant value to UCB’s drug development portfolio. This collaboration is validation of Nodality’s unique technological approach and of the value the SCNP platform technology can bring to pharmaceutical drug development. We look forward to a close and productive working relationship with UCB’s research and development teams."

Ismail Kola, Executive Vice President and President, NewMedicines at UCB said, “We look forward to the Nodality collaboration as we advance UCB’s Research & Development pipeline. This collaboration represents a key component of UCB’s strategy to innovate on the paradigm of drug development through an enhanced understanding of disease pathways and drug mechanisms in order to realize the potential for patient stratification, targeted treatments and improved care for patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UCB and Oxford University Announce New R&D Partnership
New collaboration to develop innovative research in immunology and neurology.
Monday, April 02, 2012
Scientific News
Small Molecules Lead to Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Drug Leads Identified to Combat Heart Disease
Using three supercomputers, researchers surveyed protein structures through accelerated molecular dynamics.
Accelerating Path to Molecules for Medicine
Researchers convert carbon-hydrogen bonds into nitriles - converting organic molecules into components of medicines.
Game Changing Antibacterial Drug Research
Researchers publish report on the synthesis of a newly discovered “game-changing” antibiotic, Teixobactin.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
New Way of Displaying 3D Molecular Structures
Metal-organic frameworks provide a new platform for solving the structure of hard-to-study samples.
Agent Blocks Pain Without Morphine's Side Effects
Scientists have synthesised a molecule with specific pain-relief properties and has shown its efficacy in mice.
Cutting the Cost of Drug-Building Chemicals
EPFL scientists have developed a method to produce aryl-containing amines in a cheap and easily scalable way.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!